NVAX
Income statement / Annual
Last year (2023), Novavax, Inc.'s total revenue was $983.71 M,
a decrease of 38.48% from the previous year.
In 2023, Novavax, Inc.'s net income was -$545.06 M.
See Novavax, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$983.71 M
|
$1.60 B
|
$1.15 B
|
$475.60 M
|
$18.66 M
|
$34.29 M
|
$31.18 M
|
$15.35 M
|
$36.25 M
|
$30.66 M
|
| Cost of Revenue |
$343.77 M |
$902.64 M |
$12.66 M |
$747.03 M |
$113.84 M |
$0.00 |
$0.00 |
$237.94 M |
$162.64 M |
$14.99 M |
| Gross Profit |
$639.94 M |
$696.31 M |
$1.13 B |
-$271.43 M |
-$95.18 M |
$34.29 M |
$31.18 M |
-$222.59 M |
-$126.39 M |
$15.67 M |
| Gross Profit Ratio |
0.65 |
0.44 |
0.99 |
-0.57 |
-5.1 |
1 |
1 |
-14.5 |
-3.49 |
0.51 |
| Research and Development
Expenses |
$737.50 M
|
$1.24 B
|
$2.53 B
|
$747.03 M
|
$113.84 M
|
$173.80 M
|
$168.44 M
|
$237.94 M
|
$162.64 M
|
$79.44 M
|
| General & Administrative
Expenses |
$0.00
|
$488.69 M
|
$298.36 M
|
$145.29 M
|
$34.42 M
|
$34.41 M
|
$34.45 M
|
$46.53 M
|
$30.84 M
|
$19.93 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$468.95 M
|
$488.69 M
|
$298.36 M
|
$145.29 M
|
$34.42 M
|
$34.41 M
|
$34.45 M
|
$46.53 M
|
$30.84 M
|
$19.93 M
|
| Other Expenses |
-$427.32 M |
-$382.92 M |
-$8.20 M |
$12.59 M |
-$13,000.00 |
$108,000.00 |
$67,000.00 |
-$31,000.00 |
-$120,000.00 |
$74.99 M |
| Operating Expenses |
$779.13 M |
$1.34 B |
$2.83 B |
$892.32 M |
$148.26 M |
$208.21 M |
$202.89 M |
$284.47 M |
$193.49 M |
$99.36 M |
| Cost And Expenses |
$1.55 B |
$2.24 B |
$2.83 B |
$892.32 M |
$148.26 M |
$208.21 M |
$202.89 M |
$284.47 M |
$193.49 M |
$114.35 M |
| Interest Income |
$0.00 |
$19.88 M |
$1.36 M |
$1.01 M |
$1.51 M |
$0.00 |
$1.95 M |
$0.00 |
$660,000.00 |
$286,000.00 |
| Interest Expense |
$14.42 M |
$19.88 M |
$21.13 M |
$15.15 M |
$12.19 M |
$12.19 M |
$14.07 M |
$12.97 M |
$241,000.00 |
$157,000.00 |
| Depreciation &
Amortization |
$41.23 M
|
$29.05 M
|
$12.66 M
|
$4.89 M
|
$5.80 M
|
$8.16 M
|
$9.82 M
|
$8.51 M
|
$5.98 M
|
$4.42 M
|
| EBITDA |
-$487.39 M
|
-$604.71 M
|
-$1.68 B
|
-$398.23 M
|
-$114.83 M
|
-$162.98 M
|
-$159.88 M
|
-$258.50 M
|
-$150.71 M
|
-$78.37 M
|
| EBITDA Ratio |
-0.5 |
-0.4 |
-1.47 |
-0.88 |
-7.43 |
-5.07 |
-5.51 |
-17.53 |
-4.34 |
-2.75 |
| Operating Income Ratio
|
-0.58
|
-0.4
|
-1.47
|
-0.88
|
-6.46
|
-5.07
|
-5.51
|
-17.53
|
-4.34
|
-2.73
|
| Total Other
Income/Expenses Net |
$23.48 M
|
-$8.91 M
|
-$27.96 M
|
-$1.54 M
|
-$12.11 M
|
-$10.83 M
|
-$12.06 M
|
-$10.85 M
|
$299,000.00
|
$744,000.00
|
| Income Before Tax |
-$543.03 M |
-$653.65 M |
-$1.71 B |
-$418.26 M |
-$132.69 M |
-$184.75 M |
-$183.77 M |
-$279.97 M |
-$156.94 M |
-$82.95 M |
| Income Before Tax Ratio
|
-0.55
|
-0.41
|
-1.5
|
-0.88
|
-7.11
|
-5.39
|
-5.89
|
-18.24
|
-4.33
|
-2.71
|
| Income Tax Expense |
$2.03 M |
$4.29 M |
$29.22 M |
$9.25 M |
-$2.59 M |
$1.36 M |
$2.31 M |
$2.32 M |
-$6.40 M |
-$5.17 M |
| Net Income |
-$545.06 M |
-$657.94 M |
-$1.74 B |
-$427.51 M |
-$130.10 M |
-$184.75 M |
-$183.77 M |
-$279.97 M |
-$156.94 M |
-$82.95 M |
| Net Income Ratio |
-0.55 |
-0.41 |
-1.52 |
-0.9 |
-6.97 |
-5.39 |
-5.89 |
-18.24 |
-4.33 |
-2.71 |
| EPS |
-5.41 |
-8.42 |
-23.44 |
-7.43 |
-5.4 |
-9.99 |
-12.56 |
-20.68 |
-11.97 |
-7.35 |
| EPS Diluted |
-5.41 |
-8.42 |
-23.44 |
-7.43 |
-5.4 |
-9.99 |
-12.56 |
-20.68 |
-11.97 |
-7.35 |
| Weighted Average Shares
Out |
$100.77 M
|
$78.18 M
|
$74.40 M
|
$57.55 M
|
$24.10 M
|
$18.49 M
|
$14.63 M
|
$13.54 M
|
$13.11 M
|
$11.29 M
|
| Weighted Average Shares
Out Diluted |
$100.77 M
|
$78.18 M
|
$74.40 M
|
$57.55 M
|
$24.10 M
|
$18.49 M
|
$14.63 M
|
$13.54 M
|
$13.11 M
|
$11.29 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
